Skip to search formSkip to main contentSkip to account menu

ABT-578

Known as: ABT 578, ABT578 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Drug-eluting stents have been shown to reduce the rate of restenosis significantly in all types of lesion, patient and clinical… 
2005
2005
Stent‐based delivery of the antiproliferative and immunosuppressive macrocyclic lactone sirolimus reduces neointimal formation… 
2005
2005
AbstractObjective: ABT-578, a tetrazole analogue of sirolimus (rapamycin), possesses anti-restenosis activity. The aim of this… 
2005
2005
ABT‐578, a sirolimus analog, is being developed for administration from drug‐eluting stents to prevent postimplantation… 
2005
2005
  • T. Pagano
  • 2005
  • Corpus ID: 34024654
Complete 1H and 13C assignments of 40‐epi‐(N1‐tetrazolyl)‐rapamycin (ABT‐578) in DMSO‐d6 were made using 1H, 13C, DQCOSY, ROESY… 
Review
2004
Review
2004
Abstract.ABT-578 is a new synthetic analog of rapamycin, designed to inhibit smooth muscle cell proliferation—a key contributor… 
Review
2004
Review
2004
The use of drugeluting stents (DES) has tackled the "Achilles' heel" of percutaneous coronary interventions (PCI) like no…